Biocompatible Microemulsion Modifies the Tissue Distribution of Doxorubicin

Autor(es)

Candido, Caroline Damico ^[1] ; Campos, Michel Leandro ^[1] ; Correa Vidigal Assumpcao, Juliana Uruguay ^[1] ; Pestana, Kelly Chrystina ^[1] ; Padilha, Elias Carvalho ^[1] ; Carlos, Iracilda Zeppone ^[2] ; Peccinini, Rosangela Goncalves ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Dept Nat Act Principles & Toxicol, BR-14801902 Araraquara, SP - Brazil

^[2] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Dept Clin Anal, BR-14801902 Araraquara, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Journal of Pharmaceutical Sciences; v. 103, n. 10, p. 3297-3301, OCT 2014.
• Citações Web of Science: 2

Resumo

The incorporation of doxorubicin (DOX) in a microemulsion (DOX-ME) has shown beneficial consequences by reducing the cardiotoxic effects of DOX. The aim of this study was to determine the distribution of DOX-ME in Ehrlich solid tumor (EST) and the heart, and compare it with that of free DOX. The distribution study was conducted with female Swiss mice with EST (n = 7 per group; 20-25 g). Animals received a single dose (10 mg/kg, i.p.) of DOX or DOX-ME 7 days after tumor inoculation. Fifteen minutes after administration, the animals were sacrificed, and the tumor and heart tissues were taken for immediate analysis by ultra-performance liquid chromatography. No difference was observed in DOX concentration in tumor tissue between DOX and DOX-ME administration. However, the most remarkable result in this study was the statistically significant reduction in DOX concentration in heart tissue of animals given DOX-ME. Mean DOX concentration in heart tissue was 0.92 +/- 0.54 ng mg(-1) for DOX-ME and 1.85 +/- 0.34 ng mg(-1) for free DOX. In conclusion, DOX-ME provides a better tissue distribution profile, with a lower drug concentration in heart tissue but still comparable tumor drug concentration, which indicates that antitumor activity would not be compromised. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3297-3301, 2014 (AU)

• Processo FAPESP: 11/11239-9 - Farmacocinética pré-clínica de novos fármacos e medicamentos
• Beneficiário: Rosangela Gonçalves Peccinini
• Modalidade de apoio: Auxílio à Pesquisa - Regular